Market Closed -
London S.E.
11:35:05 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
103
GBX
|
+1.58%
|
|
+4.04%
|
+19.91%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
817.7
|
725.7
|
868.2
|
847.6
|
892.2
|
1,070
|
-
|
-
|
Enterprise Value (EV)
1 |
1,223
|
9.652
|
1,136
|
1,073
|
1,032
|
4,189
|
4,189
|
4,189
|
P/E ratio
|
2.82
x
|
4.4
x
|
-24.4
x
|
-3.44
x
|
7.67
x
|
16.6
x
|
12.8
x
|
11.5
x
|
Yield
|
-
|
-
|
1.2%
|
2.12%
|
2.42%
|
2.25%
|
2.59%
|
3.55%
|
Capitalization / Revenue
|
0.35
x
|
0.25
x
|
0.33
x
|
0.27
x
|
0.23
x
|
0.23
x
|
0.2
x
|
0.18
x
|
EV / Revenue
|
0.52
x
|
0
x
|
0.43
x
|
0.34
x
|
0.27
x
|
0.91
x
|
0.8
x
|
0.71
x
|
EV / EBITDA
|
-
|
30,087
x
|
4,843,066
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
0.35
x
|
0.29
x
|
0.36
x
|
0.39
x
|
0.37
x
|
0.44
x
|
0.58
x
|
0.98
x
|
Nbr of stocks (in thousands)
|
1,035,082
|
1,038,129
|
1,038,497
|
1,038,703
|
1,038,703
|
1,038,703
|
-
|
-
|
Reference price
2 |
0.7900
|
0.6990
|
0.8360
|
0.8160
|
0.8590
|
1.030
|
1.030
|
1.030
|
Announcement Date
|
3/12/20
|
3/16/21
|
3/10/22
|
3/7/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,361
|
2,856
|
2,653
|
3,120
|
3,893
|
4,619
|
5,247
|
5,876
|
EBITDA
|
-
|
320.8
|
234.6
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
266.4
|
297
|
210
|
249
|
377
|
444.4
|
493.9
|
563.8
|
Operating Margin
|
11.29%
|
10.4%
|
7.92%
|
7.98%
|
9.68%
|
9.62%
|
9.41%
|
9.6%
|
Earnings before Tax (EBT)
1 |
368.6
|
236.7
|
-21.4
|
-317.4
|
172
|
210.2
|
210.1
|
180.4
|
Net income
1 |
302.6
|
193.6
|
-15
|
-231.1
|
129
|
87.58
|
109.7
|
126.7
|
Net margin
|
12.82%
|
6.78%
|
-0.57%
|
-7.41%
|
3.31%
|
1.9%
|
2.09%
|
2.16%
|
EPS
2 |
0.2800
|
0.1589
|
-0.0342
|
-0.2370
|
0.1120
|
0.0622
|
0.0806
|
0.0892
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.0100
|
0.0173
|
0.0208
|
0.0232
|
0.0266
|
0.0366
|
Announcement Date
|
3/12/20
|
3/16/21
|
3/10/22
|
3/7/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2021 S1
|
2022 S1
|
2023 S1
|
---|
Net sales
1 |
-
|
-
|
-
|
880
|
1,899
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
152.2
|
116.6
|
118.2
|
73.6
|
173
|
Operating Margin
|
-
|
-
|
-
|
8.36%
|
9.11%
|
Earnings before Tax (EBT)
|
243.3
|
-
|
-
|
-
|
-
|
Net income
|
-
|
246.6
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
0.2239
|
-0.0784
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.005000
|
-
|
Announcement Date
|
3/12/20
|
8/13/20
|
8/12/21
|
8/9/22
|
8/15/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
405
|
-
|
268
|
226
|
140
|
3,119
|
3,119
|
3,119
|
Net Cash position
1 |
-
|
716
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
1.142
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
15.2%
|
8.04%
|
7.82%
|
-10%
|
11.2%
|
11.6%
|
12.1%
|
12.9%
|
ROA (Net income/ Total Assets)
|
1.17%
|
0.71%
|
0.68%
|
-0.83%
|
0.44%
|
0.23%
|
0.26%
|
0.28%
|
Assets
1 |
25,885
|
27,100
|
-2,197
|
27,730
|
29,126
|
37,590
|
42,040
|
45,262
|
Book Value Per Share
2 |
2.240
|
2.400
|
2.350
|
2.100
|
2.350
|
2.330
|
1.770
|
1.060
|
Cash Flow per Share
|
-
|
-
|
-0.5900
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/16/21
|
3/10/22
|
3/7/23
|
3/8/24
|
-
|
-
|
-
|
Last Close Price
1.03
GBP Average target price
1.379
GBP Spread / Average Target +33.84% Consensus |
1st Jan change
|
Capi.
|
---|
| +19.91% | 1.33B | | +6.49% | 50.92B | | +1.35% | 48.11B | | +9.53% | 42.2B | | +6.55% | 39.71B | | +19.34% | 37.78B | | +2.84% | 30.07B | | -7.77% | 27.56B | | -18.42% | 24.71B | | +6.89% | 21.99B |
Other Life & Health Insurance
|